Onco Wiki / Bandeira vermelha

Exposição profissional histórica documentada a herbicidas à base de glifosato (mais...

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDRF-OCC-GLYPHOSATE-PREVENTION
TipoSinal de alerta
Estadoreviewed 2026-05-19 | pending_clinical_signoff
DoençasDIS-DLBCL-NOS
FontesSRC-NCCN-BCELL-2025

Origem da bandeira vermelha

DefiniçãoDocumented historical occupational exposure to glyphosate-based herbicides (most notably Roundup® and generic equivalents) — typical high-exposure occupations include agricultural workers (row-crop, orchard, and vineyard pesticide applicators), groundskeepers and landscape-maintenance staff (golf-course, parks, right-of-way), forestry workers, railroad-track vegetation control, and farm-family members involved in mixing / loading / application — with cumulative high-frequency exposure ≥10 years — in an individual without a current glyphosate-attributable malignancy diagnosis. IARC Monograph 112 (2015) classified glyphosate as Group 2A (probably carcinogenic to humans) — limited evidence in humans (positive associations with non-Hodgkin lymphoma, particularly diffuse-large-B-cell lymphoma, across multiple agricultural-cohort studies; chance / bias / confounding by other pesticides not fu...
Direcção clínicainvestigar
CategoriaOutros

Lógica de Desencadeamento

{
  "any_of": [
    {
      "finding": "occupational_glyphosate_exposure_documented",
      "value": true
    },
    {
      "finding": "occupational_glyphosate_exposure_years_ge_10",
      "value": true
    },
    {
      "finding": "occupational_agricultural_pesticide_high_frequency",
      "value": true
    }
  ],
  "type": "lab_value"
}

Notas

Prevention-persona RedFlag — v0.3 IARC 2A probable-carcinogen batch (2026-05-19). IARC Group 2A probable — limited human evidence; clinical recommendation more conservative than Group 1. IARC Monograph 112 (2015) is the canonical evidence anchor and is NOT yet a separate SRC entity in KB; cited in notes only. Evidence-base contestation: the IARC Group 2A classification is not concordant with EFSA / EPA / Health Canada / JMPR "unlikely to pose carcinogenic risk" conclusions. This RF is authored at severity:minor reflecting both the IARC 2A probable evidence quality AND the cross-regulatory disagreement. Counseling should disclose the controversy honestly rather than presenting IARC as settled science. Anchor scope: DLBCL only (the dominant NHL endpoint in IARC 112 limited-human-evidence summary). Other NHL subtypes (follicular, marginal zone, etc.) and other hematologic malignancies (MM, AML) carry inadequate or more-contested evidence and are deliberately excluded from relevant_diseases. Engine routes to 2-track PreventionPlan: (a) IND-OCC-GLYPHOSATE-PREVENTION-INTENSIFIED-SURVEILLANCE (standard) — symptom-awareness education, annual CBC, targeted lymphadenopathy / B-symptom histo...

Usado por

Indicação